Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

par Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ
Publié 2017

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

par Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, Lin I, Emond B
Publié 2021

Recurrent ruptured abdominal aneurysms in polyarteritis nodosa successfully treated with infliximab

par Lerkvaleekul B, Treepongkaruna S, Ruangwattanapaisarn N, Treesit T, Vilaiyuk S
Publié 2019

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterolo...

par Alvisi P, Arrigo S, Cucchiara S, Lionetti P, Miele E, Romano C, Ravelli A, Knafelz D, Martelossi S, Guariso G, Accomando S, Zuin G, De Giacomo C, Balzani L, Gennari M, Aloi M
Publié 2019

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease

par Sara Salvador-Martín, Alejandra Melgarejo-Ortuño, Luis A. López-Fernández
Publié 2021

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

par David Ternant, Olivier Le Tilly, Laurence Picon, Driffa Moussata, Christophe Passot, Theodora Bejan-Angoulvant, Céline Desvignes, Denis Mulleman, Philippe Goupille, Gilles Paintaud
Publié 2021

Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results

par Nozaki Y, Nagare Y, Ashida C, Tomita D, Okada A, Inoue A, Kinoshita K, Funauchi M, Matsumura I
Publié 2018

Sympathetic Ophthalmia: Where Do We Currently Stand on Treatment Strategies?

par Paulbuddhe V, Addya S, Gurnani B, Singh D, Tripathy K, Chawla R
Publié 2021

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?

par Viscido A, Papi C, Latella G, Frieri G
Publié 2019

ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES

par E. V. Voronina, N. V. Lobanova, I. R. Yakhin, N. A. Romanova, Yu. A. Seregin
Publié 2018

DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION

par E. S. Zhugrova, V. I. Mazurov, A. M. Lila, K. A. Syssoev, S. V. Lapin, Areg A. Totolian
Publié 2014

Remicade® (infliximab): 20 years of contributions to science and medicine

par Melsheimer R, Geldhof A, Apaolaza I, Schaible T
Publié 2019

Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction data...

par Tuhin Maity, Christopher Longo
Publié 2021

Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin

par Cao Y, Dai Y, Zhang L, Wang D, Hu W, Yu Q, Wang X, Yu P, Liu W, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z
Publié 2021

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

par Rawla P, Sunkara T, Raj JP
Publié 2018